What is Neuronetics?
Headquartered in Malvern, Pennsylvania, Neuronetics is the industry leader in TMS technology. Its flagship product, NeuroStar Advanced Therapy, is supported by an extensive body of clinical evidence, distinguishing it from competitors in the mental health space. The company operates not merely as a device manufacturer but as a comprehensive partner to medical practices, providing the infrastructure and ongoing support necessary to integrate advanced neuro-stimulation into standard clinical workflows. By focusing on evidence-based outcomes, Neuronetics has effectively bridged the gap between complex neurological research and practical, scalable mental health care.
How much funding has Neuronetics raised?
Neuronetics has raised a total of $90M across 2 funding rounds:
Series E
$30M
Debt
$60M
Series E (2021): $30M with participation from Polaris Partners and Pfizer
Debt (2023): $60M led by SLR Capital Partners, LLC
Key Investors in Neuronetics
SLR Capital Partners, LLC
SLR Capital Partners, LLC is a leading independent asset manager with significant permanent capital focused on delivering flexible debt capital solutions to U.S. based middle market businesses.
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing coaching and resources for growth.
Pfizer
Pfizer is a global biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas.
What's next for Neuronetics?
With the recent influx of capital, Neuronetics is well-positioned to accelerate its strategic initiatives. The company is expected to prioritize the expansion of its commercial reach and the enhancement of its support services for clinical partners. Given the current enterprise-level funding context, the focus will likely shift toward optimizing operational efficiencies and scaling the adoption of NeuroStar technology. As the mental health sector continues to prioritize non-pharmacological interventions, Neuronetics' commitment to clinical rigor and technological innovation will be critical in maintaining its competitive advantage and driving long-term value for stakeholders.
See full Neuronetics company page
